NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/24/2023
Back to search
Official data from USPTO
SAGA DIAGNOSTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
47
Latest update
07/24/2023
Trademark type
Combined
Nice classes
5, 42, 44
Filing date
03/05/2020
Registration date
10/05/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/05/2021
Last transaction
10/05/2021
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
99
Owner location
SE
Examiner
CARROLL, DORITT
Law office
M70
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of "SAGA" in black capital letters with the left bar of each letter "A" composed of one indigo and one red rectangle. Below it the word "DIAGNOSTICS" appears in smaller black capital letters.
Holders and representatives
Holders
SAGA Diagnostics AB
Representatives
Sarah J. Schneider Sheridan Ross P.C.
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Biopharmaceuticals for the treatment of cancer; pharmaceutical preparations for the treatment of cancer; biological preparations for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; chemical preparations for use in DNA analysis for medical purposes; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for the prevention of tumours; tumor suppressing agents; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for treating malignant tumors; nucleic acid sequences for medical and veterinary purposes; medical diagnostic reagents and assays for testing of body fluids; clinical medical reagents; veterinary diagnostic reagents; medical diagnostic reagents; reagents for medical use; chemical reagents for veterinary use; chemical reagents for medical use; reagents for microbiological analysis for veterinary use; reagents for microbiological analysis for medical use; diagnostic reagents for medical use; diagnostic reagents for medicinal use; immunoassay reagents for medical use; diagnostic biomarker reagents for medical purposes; diagnostic chemical reagents for medical use; chemical diagnostic reagents for medical use; reagents for analytical purposes for medical purposes; reagents for blood grouping for medical purposes; reagents for microbiological analysis for medical purposes; reagents for analytical purposes for veterinary purposes; reagents for microbiological analysis for veterinary purposes; reagents for use in diagnostic pregnancy tests; chemical reagents for medical or veterinary purposes; reagents for use in analysis for veterinary purposes; reagents for use in analysis for medical purposes; reagents for use with analyzers for medical purposes; reagents for use with analyzers for veterinary purposes; reagents for use in diagnostic tests for medical purposes; reagents for use in diagnostic tests for veterinary purposes; reagents for in-vitro laboratory use for medical purposes; reagents and media for medical and veterinary diagnostic purposes; reagents for in-vitro laboratory use for veterinary purposes; genetic identity tests comprised of reagents for medical purposes; medical diagnostic reagents and assays for testing of body fluids; reagents for use in veterinary genetic testing; genetic identity tests comprised of reagents for medical purposes
Class 42
Scientific research for medical purposes in the area of cancerous diseases; scientific laboratory serviceslaboratory research services relating to detection of sequence variants in DNA or RNA; laboratory testing services relating to detection of sequence variants in DNA or RNA; analytical medical laboratory services; analytical veterinary laboratory services; scientific laboratory services; medical laboratory services; veterinary laboratory services; medical chemical laboratory services; medical biological laboratory services; medical research laboratory services; medical chemical research laboratory services; medical biological research laboratory services; medical laboratory services for analytical testing; medical services of a chemical laboratory; DNA testing services to determine paternity laboratory services; laboratory research services relating to dermatology; laboratory research services relating to pharmaceuticals; medical services of a chemical and/or biological laboratory; medical laboratory services relating to the production of monoclonal antibodies; DNA screening for scientific research purposes; clinical trials for others; conducting clinical trials for others; conducting clinical trials for pharmaceutical products for others; conducting clinical trials in the field of cardiovascular disease for others; conducting clinical trials in the field of acupuncture therapy for others; providing information about the results of clinical trials for pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; clinical research in the field of cancer and infectious diseases; biological researchclinical research and medical research; basic and clinical research in the field of respiratory science and medicine; pharmaceutical research services; research on the subject of pharmaceuticals; pharmaceutical research and development; research relating to pharmaceuticals; pharmaceutical research and development services; laboratory research services relating to pharmaceuticals; research on the subject of pharmaceuticals; consultancy relating to pharmaceutical research and development; research and development for the pharmaceutical industry; consultancy in the field of pharmaceutical research; research and development in the pharmaceutical and biotechnology fields; scientific researchgenetic engineering services; scientific research in the field of genetics and genetic engineering; scientific research relating to genetics; genetic testing for scientific research purposes; scientific researchgenetic engineering services relating to plants; medical research in the field of gene therapy; scientific research relating to genetics of plants; laboratory research in the field of gene expression; genetic testing of laboratory animals for research purposes
Class 44
Lung cancer screening services; prostate cancer screening services; breast cancer screening services; bowel cancer screening services; cervical cancer screening services; providing cancer screening services; testicular cancer screening services; medical analysis services for the diagnosis of cancer; medical analysis services for cancer diagnosis and prognosis; medical services for the treatment of skin cancer; RNA or DNA analysis for cancer diagnosis and prognosis provided by medical laboratories; genetic testing of animals for diagnostic or treatment purposes; medical testing for diagnostic or treatment purposes; DNA screening for medical purposes; drugalcohol and DNA screening for medical purposes; RNA or DNA analysis for cancer diagnosis and prognosis; medical and health services relating to DNAgenetics and genetic testing; genetic counseling; genetic testing of animals for diagnostic or treatment purposes; genetic testing for medical purposes; genetic testing of animals for diagnostic or treatment purposes
Publications
History of USPTO decisions and trademark events.
47 publications found
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
12/15/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/15/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
12/15/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/15/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/15/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
12/15/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
04/18/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
03/24/2022
FIMP
FINAL DISPOSITION PROCESSED
03/24/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
01/21/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/05/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
10/05/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/20/2021
PUBO
PUBLISHED FOR OPPOSITION
07/20/2021
GPNX
NOTIFICATION PROCESSED BY IB
07/19/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
06/30/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
06/30/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/30/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/14/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
06/14/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
06/14/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
06/14/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
06/14/2021
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
06/01/2021
GNFR
FINAL REFUSAL E-MAILED
06/01/2021
CNFR
FINAL REFUSAL WRITTEN
06/01/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/01/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/30/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/30/2021
RFNT
REFUSAL PROCESSED BY IB
01/04/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
12/11/2020
RFRR
REFUSAL PROCESSED BY MPU
12/11/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/26/2020
CNRT
NON-FINAL ACTION WRITTEN
11/25/2020
MAFR
APPLICATION FILING RECEIPT MAILED
11/24/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
11/19/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
11/19/2020
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
11/19/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
11/19/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
11/19/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
11/19/2020
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
11/18/2020
DOCK
ASSIGNED TO EXAMINER
11/18/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/18/2020
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/13/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/22/2020
Continuous trademark protection
Get notified about every new filing that threatens SAGA DIAGNOSTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.